- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OCULIS Aktie jetzt für 0€ handeln | |||||
| Di | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 5 | GlobeNewswire (USA) | ||
| Di | Oculis Holding AG: Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 | 5 | GlobeNewswire (USA) | ||
| 08.10. | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 2 | GlobeNewswire (USA) | ||
| 07.10. | Oculis stock price target raised to $36 from $33 at H.C. Wainwright | 2 | Investing.com | ||
| 06.10. | Oculis Holding AG - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 06.10. | Oculis takes second eye disease therapy into pivotal trials | 3 | pharmaphorum | ||
| 06.10. | Oculis Holding AG: Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy | 332 | GlobeNewswire (Europe) | Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch... ► Artikel lesen | |
| 26.09. | Oculis Holding AG: Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities | 3 | GlobeNewswire (USA) | ||
| 22.09. | Oculis Holding AG: Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS | 2 | GlobeNewswire (USA) | ||
| 09.09. | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 2 | GlobeNewswire (USA) | ||
| 04.09. | Oculis Holding AG: Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025 | 2 | GlobeNewswire (USA) | ||
| 03.09. | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 6 | GlobeNewswire (USA) | ||
| 27.08. | Needham initiates Oculis Holding stock with Buy rating on eye disease portfolio | 7 | Investing.com | ||
| 25.08. | Oculis Holding AG: Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors | 415 | GlobeNewswire (Europe) | Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple... ► Artikel lesen | |
| 22.08. | H.C. Wainwright hebt Kursziel für Oculis Holding auf 33 US-Dollar an | 4 | Investing.com Deutsch | ||
| 22.08. | Stifel reiterates Buy rating on Oculis Holding stock, maintains $35 target | 7 | Investing.com | ||
| 22.08. | Stifel bestätigt Kaufempfehlung für Oculis und Kursziel von 35 US-Dollar | 6 | Investing.com Deutsch | ||
| 21.08. | Oculis Holding AG - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 21.08. | Oculis Holding AG: Oculis Reports Q2 2025 Financial Results and Provides Company Update | 664 | GlobeNewswire (Europe) | ZUG, Switzerland, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Focused execution in Q2 2025 to advance Oculis' pipeline in ophthalmology and neuro-ophthalmology. OCS-01: Both pivotal Ph3 DIAMOND trials are fully... ► Artikel lesen | |
| 11.08. | Oculis erhöht Kreditvereinbarung auf bis zu 100 Millionen Franken | 3 | punkt4.info |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,576 | -4,36 % | Alternative zu BioNTec, Evotec und Co.: BioNxt Solutions überzeugt auf Investorenkonferenz und weckt Übernahmefantasie | Während die Aktien von BioNTech und Evotec auf der Stelle treten, befindet sich BioNxt Solutions im Aufwärtstrend. Denn das Unternehmen mischt gerade Big Pharma auf. Die Ankündigung, die Abnehmspritze... ► Artikel lesen | |
| QIAGEN | 41,345 | +0,29 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 59,00 | -0,84 % | CRISPR THERAPEUTICS AG verharrt - jetzt wird's brenzlig! | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 9,090 | -3,19 % | Aktien New York: Stabil - Anleger trotz 'Shutdown'-Gefahr gelassen | NEW YORK (dpa-AFX) - Nach dem Rekordlauf der US-Börsen vor einer Woche und darauf folgenden Verlusten hat die US-Technologiebörse Nasdaq am Montag erneut zugelegt. Allerdings bröckelten die Gewinne... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 189,99 | +16,77 % | Praxis Precision Medicines prices $525M public offering | ||
| RANI THERAPEUTICS | 1,640 | +248,20 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| NUVALENT | 92,52 | +2,32 % | Stifel initiates coverage on Nuvalent stock with Buy rating | ||
| RECURSION PHARMACEUTICALS | 5,860 | -7,86 % | Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event | ||
| KYMERA THERAPEUTICS | 59,83 | -1,11 % | The Analyst Verdict: Kymera Therapeutics In The Eyes Of 6 Experts | ||
| IMMUNOVANT | 17,510 | +0,57 % | Truist Securities initiates Immunovant stock with Hold rating, $16 target | ||
| COGENT BIOSCIENCES | 16,390 | +0,18 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| TREVI THERAPEUTICS | 10,360 | -2,45 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 5,030 | -5,18 % | Sana Biotech surges as Eric Jackson calls it a 100-bagger | ||
| ARTIVA BIOTHERAPEUTICS | 6,020 | +118,12 % | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update | Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate... ► Artikel lesen | |
| IMMUNOME | 15,670 | -5,03 % | Where Immunome Stands With Analysts |
OCULIS HOLDING AG gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,200 (+1,11 %) liegt der Kurs bei 18,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OCULIS HOLDING AG finden Sie auf Wallstreet Online.